• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

News

 Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer
0
By Nascent Biotech
In Science News
Posted August 22, 2023

Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer

NORTH PALM BEACH, FL / ACCESSWIRE / August 22, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 Benzinga: Why NBIO is a Biotech Bargain Basement Deal with Underappreciated Potential
0
By Nascent Biotech
In Science News
Posted July 12, 2023

Benzinga: Why NBIO is a Biotech Bargain Basement Deal with Underappreciated Potential

We came across Nascent Biotech Inc. NBIO last year and it caught our eye despite still trading on the OTC for just pennies per share. The share price of a stock isn’t a very important [...]

READ MORE
 Journal of Clinical Oncology: Phase 1 study of pritumumab in brain cancer.
0
By Nascent Biotech
In Science News
Posted June 6, 2023

Journal of Clinical Oncology: Phase 1 study of pritumumab in brain cancer.

Jose Arganda Carrillo, Santosh Kesari, Jaya Mini Gill, Charles Redfern, Sean Carrick, Ivan Babic Background: Pritumumab, a fully human IgG1 (kappa) monoclonal antibody (mAb), was originally [...]

READ MORE
 Nascent Biotech Regains Worldwide Rights for Pritumumab
0
By Nascent Biotech
In Corporate News
Posted May 27, 2023

Nascent Biotech Regains Worldwide Rights for Pritumumab

NORTH PALM BEACH, FL / ACCESSWIRE / May 26, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 NBIO Link Report for May 10, 2023
0
By Nascent Biotech
In Corporate News
Posted May 10, 2023

NBIO Link Report for May 10, 2023

Wall Street PR Apple News StreetInsider.com QuoteMedia WallStreetPR Facebook LinkedIn

READ MORE
 Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting
0
By Nascent Biotech
In Corporate News, Press Releases, Science News
Posted May 9, 2023

Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting

NORTH PALM BEACH, FL / ACCESSWIRE / May 9, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 A Letter to Nascent Biotech Shareholders, May 1, 2023
0
By Nascent Biotech
In Corporate News, News
Posted May 1, 2023

A Letter to Nascent Biotech Shareholders, May 1, 2023

Dear Shareholder, Your continued support of Nascent Biotech is very much appreciated by the Company’s management.  Without it, we could not have achieved the completion of our Phase I Clinical [...]

READ MORE
 Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval
0
By Nascent Biotech
In Corporate News, News, Press Releases, Science News
Posted April 18, 2023

Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval

NORTH PALM BEACH, FL / ACCESSWIRE / April 18, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 Nascent Announces the Completion of Its Phase 1 Clinical Trials
0
By Nascent Biotech
In Corporate News, Press Releases, Science News
Posted February 28, 2023

Nascent Announces the Completion of Its Phase 1 Clinical Trials

NORTH PALM BEACH, FL / ACCESSWIRE / February 28, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 NBIO Fits Profile for Strategy Targeting Early Stage Biotech
0
By Nascent Biotech
In Corporate News
Posted January 18, 2023

NBIO Fits Profile for Strategy Targeting Early Stage Biotech

One candidate that checks all of these boxes is Nascent Biotech Inc. (OTCMKTS:NBIO). NBIO checks all the boxes discussed above. It’s a dirt-cheap stock, trading on a market cap of just $16 [...]

READ MORE
1 2 3 4 5 6 7 8
page 1 of 8
© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.